3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Not yet recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Colorectal Neoplasms
3
Skin Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Turcot syndrome
1
Solid Tumors
1
Solid Tumor, Adult
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Motor Activity
1
Lung Neoplasms
1
Locally Advanced Esophageal Squamous Cell Carcinoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Interventions
Capecitabine
13
Fluorouracil
12
Oxaliplatin
9
Nivolumab
9
Radiotherapy
8
Leucovorin
8
Cetuximab
8
Magnetic Resonance Spectroscopy
6
Irinotecan
5
pembrolizumab
4
encorafenib
4
Surgical Procedures, Operative
4
Sigmoidoscopy
4
Radiotherapy, Intensity-Modulated
4
Surveys and Questionnaires
3
Standard of Care
3
Specimen Handling
3
Biopsy
3
Bevacizumab
3
dostarlimab
2
dehydroftorafur
2
atezolizumab
2
XELOX
2
X-Rays
2
Observation
2
Magnetic Resonance Imaging
2
Immunoglobulin G
2
Folfox protocol
2
Drug Therapy
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Rectal Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled